Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday.

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

Merck (NYSE:MRK) shares were on track to snap six straight sessions of gains on Wednesday, as the stock fell 2.8% at $88.87 ...

A higher prostate cancer behavior score was associated with a 31% reduction in the hazard for all-cause mortality and a 33% ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...